Member Info for Vertizea-Sun

From the RNS:

"and it continues to actively explore opportunities for a potential dual listing on NASDAQ."

Nearly unbelievable....but I do. And then x75.

"-In comparison with ADCs the safety profile of ava6k is much much better. So good in fact that the FDA kept asking them to check the data, as they couldn't believe the lack of lung issues and blood issues."

Is there anyone out there?

Furthermore .... No one in her position will utter a word on anything until the dust has settled on both the UK budget and the US election.

CC just told you she's moving to NASDAQ.

Is the entire commercial world sitting on their collective hands until Rachel from accounts enjoys her fifteen minutes? Thursday might be a different world.

The Telegraph has a full page on the development complete with photo of the patient. Patient confidentiality prevents Avacta doing just that claim our own armchair experts.

https://www.telegraph.co.uk/news/2024/10/29/nhs-trial-deadly-brain-cancer-shrinks-first-patient-tumour/

"What I'd really appreciate though would be a clamp down on corruption."

Indeed and it can come in many forms. Why did the British Nuclear Regulator demand 7000 changes in the design of Hinkley C (resulting in extra billions) when the French and Finnish governments built as per the original design. How many ex-regulators are employed by the constructors?

Or were you thinking of Unite:

"Serious Fraud Office probe £112m Unite union hotel"

https://www.bbc.co.uk/news/articles/cn5z54236wgo

Crowfoot....the cheap share price matters a lot because it's leaving Avacta open to an unwanted take over. I've said many times I think the board is hurrying to get Avacta on NASDAQ to prevent just that.

From the RNS and it's clearly in the plural:

"The presentations include data from two preclinical oncology assets, AVA6103 and AVA7100, from Avacta's pipeline of pre|CISION® product candidates."

And what's the point of a Science Day if it doesn't discuss the pipeline?

Monopar:

Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

Shares of the Wilmette, Ill., company were recently up 199% at $13.87, and are now more than five times higher than they were at the start of the year.

Monopar agreed to license the ALXN-1840 drug candidate for an up-front payment comprised of undisclosed amounts of cash and equity, plus future royalties and milestone payments.

Are the boardrooms of BP in denial about their investment in ADC's? I'd be angry at Avacta if I was in that position.

We need a steer on Science Day. What is Simon Bennett busy on?

"exclusive rights to affimers"

Was he not involved in the early development of the technology.....at Leeds University?

Getting exclusive rights from Bill Bachovchin for pre|CISION™ is a different matter. It would be nice to think that BB understood from the very beginning how important Affimers would be.

"audit of accounts?"

In order to prove to Avacta's auditors there will be sufficient cash for the year ahead - to allow the accounts to be signed off as a going concern. This is mainly because Avacta does not have any real commercial cash flow and relies on financial one off's.

Gje306....that's a damn shame.....there I was thinking AVA is going to be used like an aspirin.

I'm embarrassed to say it but I agree with Hurst. A few weeks ago CC pointed out a successful NASDAQ listing requires knowledge of a company's pipeline and full trial data and both will be ready for Science Day on the 30th. I say again that Darlene Deptula-Hicks is working her socks off in Wall Street to get this company listed and more protected from a take over.

I'm more convinced than ever that the top dozen people in this company want the fame that only comes with independence. It's not just money.

If Avacta is also offering access to Affimer technology then DX could conceivably be worth rather more than less.

Thank you BV and avctip.....not silly to assume an RNS tomorrow announcing HCI details.

It's too late to reform. The British government needs to keep directing as much money as possible in the direction of buying its own debt. It's not going to jeopardise that by making it easier for pension funds etc to invest in riskier options. That's why it was stopped in the first place and even if I'm wrong Starmer will spend the next year thinking about it.

I'm sure Avacta will be heading to either NASDAQ or Switzerland